Clinical Trials Browser

patritumab deruxtecan × 30 days × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06445972 2026-03-16

MK-3475-06D

Phase 1/2 Recruiting

210 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06469944 2026-03-16

MK-3475-06C

Phase 1/2 Recruiting

160 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06596694 2026-03-16

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Phase 1/2 Recruiting

180 enrolled

Gastrointestinal

Gastrointestinal Neoplasms

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

1,000 enrolled

Breast

Breast Neoplasms

NCT07286149 2026-03-16

MK-3475-01F

Phase 1/2 Recruiting

190 enrolled

Thoracic

Lung Neoplasms

NCT06941272 2026-03-13

MK-9999-01C

Phase 1/2 Recruiting

50 enrolled

Tumor-Agnostic

Neoplasms

NCT05865990 2026-03-12

TUXEDO-3

Phase 2 Active not recruiting

63 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms

NCT03260491 2026-03-05

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

312 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT06731907 2026-02-18

MK-3475-01G

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

MK-3475-01A

MK-3475-06D

MK-3475-06C

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

MK-3475-01F

MK-9999-01C

TUXEDO-3

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

MK-3475-01G